



Sponsored by **UROVANT[®]**
SCIENCES

Please join us for an upcoming program

**Discover the Impact of GEMTESA[®], An Effective OAB Treatment:
A Fresh Look at OAB Management in Long-Term Care Settings**

FACULTY

JOHN AVOLIO, PD
INDIANA, PA

DATE/TIME

09/09/2021
6:30 PM Eastern

LOCATION

Hyde Park Pittsburgh
247 North Shore Drive
Pittsburgh, PA 15212

RSVP TO

Sarah Kennedy
412-667-8813
sarah.kennedy@urovant.com

RSVP BY

*As soon as possible as
space is limited 1-866-700-9296*

INDICATION AND USAGE

GEMTESA[®] (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product.

WARNINGS AND PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 2\%$) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

[Please see full Prescribing information.](#)



GEMTESA[®]
(vibegron) 75 mg
tablets



TRANSPARENCY NOTIFICATION

Urovant Sciences, Inc. ("Urovant") will report payments and transfers of value to healthcare professionals in accordance with all Federal and State reporting requirements. This may include the reporting of meals provided to office staff.

Urovant is not permitted to provide meals to healthcare professionals in **Vermont** or **Minnesota**.

New Jersey licensed prescribers are not to accept breakfast or lunch valued over \$15 and dinner over \$30.

You may opt-out of the meal for this event. Please inform the program organizer if you would like to do so.

[If you no longer wish to receive emails about this program, please unsubscribe.](#)

UROVANT®
SCIENCES

UROVANT, UROVANT SCIENCES, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

©2021 Urovant Sciences. All rights reserved. Printed in USA. US-VBGN-2100094 March 2021